Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children
Background:
Broadly neutralizing monoclonal antibodies (bNAbs) suppress HIV-1 RNA and may deplete residual viral reservoirs. We evaluated the safety and pharmacokinetics (PK) of dual intravenous VRC01LS and 10-1074 in very early-treated children with HIV-1 on suppressive antiretroviral treatment (ART).
Setting:
Botswana.
Methods:
Children with HIV-1 (median age 3.1 years) on ART from
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - Category: Infectious Diseases Tags: Clinical Science Source Type: research